Carole Ben Maimon | Chief Executive Officer
Chondrial Therapeutics

Carole Ben Maimon, Chief Executive Officer, Chondrial Therapeutics

Carole Ben-Maimon, MD joined Chondrial Therapeutics in December 2016 as the Chief Executive Officer, bringing more than 25 years experience in the pharmaceutical industry to the company. Most recently, she worked with Deerfield Management Company assisting in the evaluation of investment opportunities in the brand and generic industry. Prior to working with Deerfield, she was President of Global Pharmaceuticals, a subsidiary of Impax Laboratories that was responsible for Impax’s generic business. Dr. Ben-Maimon’s career is further highlighted by leadership roles at several pharmaceutical companies including Barr Pharmaceuticals and Teva Pharmaceutical Industries. At Barr Pharmaceuticals, Dr. Ben-Maimon served as President and COO of the company’s branded female healthcare business and was also a member of the Board of Directors. During her tenure at Teva, Dr. Ben-Maimon was responsible for R&D and public policy in North America. In addition to her executive roles, Dr. Ben-Maimon currently serves on the Board of two emerging, privately-held pharmaceutical companies and serves on the Board of a not-for-profit hospital in Philadelphia. Dr. Ben-Maimon received her B.S. from the University of Pennsylvania and her M.D. from Jefferson Medical College. She completed a residency in internal medicine and a fellowship in nephrology.


World Orphan Drug Congress USA 2018 - Conference Day One @ 15:40

Beyond “patient focused drug development” buzzwords - let’s get practical

  • Industry and patient partnerships for clinical trial design and execution, funding discussions and community  outreach
  • Patients as board members through the product lifecycle to impact the needs of the community
  • Partnering with patients in a compliant way and achieving support from government and academic institutions to drive scientific research 

back to speakers